BioSpace News Archive

BridgeBio Pharma, Inc. today announced that on October 06, 2023, the compensation committee of BridgeBio’s board of directors granted nineteen new employees restricted stock units for an aggregate of 227,507 shares of the Company’s common stock.

Matinas BioPharma announces complete clinical resolution of a patient’s recurrent hemorrhagic cystitis due to Candida krusei, a fluconazole inherited resistant fungal pathogen, following treatment with MAT2203, Matinas’ oral formulation of the potent antifungal amphotericin B.

Vivos Therapeutics, Inc. announced that its flagship daytime-nighttime appliance (DNA) will be tested in a clinical trial at Stanford Medicine.

Coeptis Therapeutics Holdings, Inc. today announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include the SNAP-CAR technology platform in natural killer (NK) cells.

IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services, and The Coalition for Epidemic Preparedness Innovations announced a strategic collaboration to advance the 100 Days Mission.

ImmPACT Bio USA , Inc. today announced that it will participate at the BIO Investor Forum, to be held from October 17-18, 2023 in San Francisco, CA.

Perimeter Medical Imaging AI, Inc. announced that patient randomization is underway at Mayo Clinic in Florida, the most recent clinical site to be initiated as part of an ongoing multi-center, randomized two-arm pivotal clinical trial evaluating the investigational Perimeter B-Series OCT combined with its proprietary ImgAssist AI software.

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced top-line findings from a recent subgroup analysis of AspyreRx (formerly BT-001) in its pivotal trial for type 2 diabetes (T2D).

Mainz Biomed NV, a leading molecular genetics diagnostic company focused on early cancer detection, announced its participation in the upcoming UEG Week.

Elicio Therapeutics, Inc. announced that it will present updated preliminary data from the ongoing Phase 1 study of its lead asset, ELI-002, targeting mutated KRAS in patients with high relapse risk pancreatic and colorectal cancers, and preclinical data on ELI-007 and ELI-008.